New drink flavors aim to help kidney patients stay nourished
NCT ID NCT06892249
First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 6 times
Summary
This study tested two flavors of a high-energy, low-protein drink called Renalive® LP in 74 adults with chronic kidney disease stages 3b-5. Participants drank the formula as a meal replacement or supplement for 4 weeks. The goal was to see if the drink was suitable and helped maintain body weight and nutrition without harming kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
74 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\<45 mL/min/1.73 m2) 2. Age: ≥18 years 3. Outpatients with instruction to keep a low protein diet (0.55-0.8 g protein /kg actual body weight/ day) in the last 3 months as evaluated by the Investigator 4. Written Informed Consent from patient Exclusion Criteria: 1. Has received dialysis or are expected to start dialysis within the next 3 months 2. Patients awaiting kidney transplant 3. Body mass index (BMI) \<18 kg/m2 or BMI \>30 kg/m2 4. Malnourished patients with albumin \<3 g/dL in need of extra calories and nutrients 5. Patients receiving or having received oral/enteral/parenteral nutrition supplementation for special medical purpose in the last 7 days 6. Severe liver disease, malignant neoplastic disease, current significant infectious disease (apart from flu, cold, Hepatitis C virus (HCV) carrier, Hepatitis B virus (HBV) carrier, skin infection) deemed unsuitable for entering the trial as evaluated by the Investigator 7. Existing gastrointestinal disease or pathological findings that cannot tolerate enteral nutrition or render enteral nutrition unfeasible, such as shock, acute upper gastrointestinal bleeding, intestinal sluggishness, intestinal obstruction, or malabsorption, such as inflammatory bowel disease, pancreatic disease, or gastrointestinal surgery 8. Severe impairment of gastrointestinal function, i.e. severe constipation or acute diarrhoea (≥3 loose or watery stools a day) 9. Swallowing difficulty or high risk of aspiration 10. Central nervous system and/or certain psychiatric disorders where the patient is considered as not yet clinically stable and/or not suitable to participate in this study by the Investigator 11. Known allergic reaction or intolerance to any ingredient of the intervention formula 12. Surgery or hospitalization scheduled during the trial 13. Suspected drug abuse 14. Unable to follow study instructions or keep a dietary diary 15. Pregnant or lactating women 16. Participation in other clinical trials using investigational drugs within 30 days before the start of the trial or during the trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaosiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
Taipei TzuChi Hospital
New Taipei City, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tracking blood markers over time may reveal hidden heart risk
- A simple blood ratio may predict diabetic kidney disease
- A new app maps kidney-friendly meals for dining out in singapore
- Can we predict who will progress quickly to kidney failure?
- Could a triple therapy beat kidney muscle wasting?
- Could a phone app be the key to managing kidney disease?